A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

por Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P., Melichar, B., Atkins, J., Nowara, E., Moyé, L., Piquemal, D., Ritter, D., Dubreuil, P., Mansfield, C. D., Acin, Y., Moussy, A., Hermine, O., Hammel, P.
Publicado 2015

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

por Van Cutsem, E, Li, C-P, Nowara, E, Aprile, G, Moore, M, Federowicz, I, Van Laethem, J-L, Hsu, C, Tham, C K, Stemmer, S M, Lipp, R, Zeaiter, A, Fittipaldo, A, Csutor, Z, Klughammer, B, Meng, X, Ciuleanu, T
Publicado 2014